Companies ›Healthcare ›BIO.AX

BIO.AX — ASX Diversified Medical Equipment & Supplies

Bio.Ax

A$0,28

Open in Charts → Attach watcher ⌖

— —

AUD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

62,7M AUD

P/E

—

EV / Rev

—

Div yield

—

Op margin

1,2 %

ROE

4,6 %

Net margin

1,2 %

Debt / equity

0,66

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

—

Open

—

Next earnings

2026-10-28

Ex-dividend

—

TR 1Y

—

About

BIO.AX operates in the pharmaceuticals industry, generating revenue primarily through the development and commercialization of healthcare products and services.

Business. BIO.AX operates in the pharmaceuticals industry, generating revenue primarily through the development and commercialization of healthcare products and services.

Classification99 %

SectorHealth Care

Industry groupDiversified Medical Equipment & Supplies

Generated · model-assisted

Sell-side consensus

BUY1 analysts

1 buy0 hold0 sell

Avg 12m price target1,00

Analyst recommendations

1 analysts · consensus Buy

Buy1

Hold0

Sell0

12-month price target

1,00

Consensus of sell-side coverage.

Upcoming events

EarningsQ3 2026 earnings (expected)2026-10-28 · estimated

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts→

Buy

1 analysts · indicative

Ownership→

Dimensional Fund Advisors, L.P.

largest disclosed fund holder

Profitability→

4,6 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning BIO.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to BIO.AX. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Company
EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR
Congressional trades
CongressSusie Lee — Bio-Rad Laboratories, Inc. Class A2022-11-30 · Democrat · NV · Sale · $1,001 - $15,000

Pre-earnings brief

Briefing · model-assisted

Bio-Rad Laboratories Inc (BIO.O) has seen significant adjustments in its shareholder registry, with major severity signals detected regarding holder changes as of March 31, 2026. Specifically, investor ID 587 reduced their position from 2,220 shares to 221 shares, while investor ID 931 experienced a dramatic fluctuation, with records showing a shift from 71,965 shares down to 11 shares, and subsequently back up to 71,965 shares. These modifications were detected between July 3 and July 7, 2026, indicating active or corrected reporting within the company's top 36 holders. Concurrently, the company’s risk profile has been updated with new assessments. Dilution risk is now classified as "low," while liquidity risk has been established at a "medium" level. These classifications were determined based on internal specification thresholds, providing a clearer framework for evaluating the financial stability and capital structure risks associated with the stock. On the classification front, Bio-Rad’s activity and economic sector taxonomy fields have been updated from null to "Unclassified." This change, marked with medium severity, reflects a gap in specific sectoral categorization within the current data model, which may impact how the company is grouped for comparative analysis against peers in the healthcare or scientific instruments sectors. Finally, the AI analysis narrative for Bio-Rad has been revised, though the specific content of the new thesis is not detailed in the available facts. This modification, also of medium severity, suggests an update to the qualitative outlook or investment thesis surrounding the company, potentially aligning with the recent changes in holder data and risk assessments. The company currently reports zero analyst coverage and zero index memberships, highlighting a niche or less-followed status in the broader market.

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

BIO.AX operates in the pharmaceuticals industry, generating revenue primarily through the development and commercialization of healthcare products and services.

Classification99 %

SectorHealth Care

Industry groupDiversified Medical Equipment & Supplies

AI synthesis

GENERATED

BIO.AX has a market capitalization of AUD 56.54 million and a price-to-earnings ratio of 263.41, indicating a high valuation relative to its earnings. The company's price-to-book ratio is 12.09, suggesting that the market values the company significantly above its book value. The enterprise value to EBITDA ratio is 277.73, which is notably high and may reflect market expectations of future earnings growth or a premium valuation.

In terms of profitability, BIO.AX has a return on equity of 4.59% and a return on assets of 1.79%, both of which are below the industry median for pharmaceutical companies. This suggests that the company is not generating returns as efficiently as its peers. The operating margin is 1.17%, and the net profit margin is also 1.17%, indicating that the company is maintaining a narrow margin on its operations.

The company's revenue is concentrated in a single segment, and there is no disclosed geographic diversification in the financial data provided. This lack of diversification could pose a risk if the company's primary market experiences a downturn. The company's revenue has not been provided for previous periods, so it is not possible to assess the growth trajectory based on historical data.

BIO.AX has a debt-to-equity ratio of 0.66, indicating a moderate level of leverage. The company's current ratio is 1.59, suggesting that it has sufficient current assets to cover its current liabilities. However, the company has a negative operating cash flow of AUD 2.82 million, which could be a concern for its liquidity position. The free cash flow is positive at AUD 256,250, which is a positive sign for the company's ability to generate cash from operations.

The risk assessment indicates a medium liquidity risk and a low dilution risk. The company has a negative net cash position after subtracting total debt, which could affect its ability to meet short-term obligations. The analyst estimates suggest a mean price target of AUD 1.00, with a mean recommendation of 2.00, indicating a neutral stance from analysts. There are no strong-buy recommendations, with only one buy recommendation and no hold recommendations.

Recent events and filings have not been provided in the data, so it is not possible to comment on any recent developments that may have affected the company's performance or outlook.

Key takeaways

BIO.AX has a high price-to-earnings ratio, indicating a premium valuation relative to its earnings.
The company's return on equity and return on assets are below the industry median, suggesting lower efficiency in generating returns.
The company's revenue is concentrated in a single segment, and there is no disclosed geographic diversification, which could pose a risk.
The company has a moderate level of leverage and a current ratio that suggests it can cover its current liabilities.
The company has a negative operating cash flow, which could be a concern for its liquidity position.
Analysts have a neutral stance on the company, with a mean price target of AUD 1.00 and a mean recommendation of 2.00.
margin_outlook_rationale: The company's operating and net profit margins are narrow, which may limit its ability to absorb cost increases or price competition.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Valuation

Market price

A$0,28

Market cap

A$56.5M

Enterprise valueⓘ

A$59.6M

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

12.1x

P / Tangible bookⓘ

12.1x

Tangible book

A$4.7M

Net cashⓘ

-A$3.1M

Current ratioⓘ

1.6

Debt / equityⓘ

0.7

ROAⓘ

1.8%

ROEⓘ

4.6%

Cash conversionⓘ

-1314.0%

CapEx / revenueⓘ

-1.1%

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Life Sciences Research & Diagnostics—

disclosed · segment_methodology

Business relationships

Business relationships56 disclosed relationships · 1 type · extracted from filings & disclosures

Subsidiaries56

EX21:021764e18c34EX21:021764e18c34Subsidiarie97%

EX21:143c3cd38595EX21:143c3cd38595Subsidiarie97%

EX21:14bd5bee4a5bEX21:14bd5bee4a5bSubsidiarie97%

EX21:1a3035efc710EX21:1a3035efc710Subsidiarie97%

EX21:1d4badc66d59EX21:1d4badc66d59Subsidiarie97%

EX21:1dc847e879d4EX21:1dc847e879d4Subsidiarie97%

EX21:1e9b3ab3cfb2EX21:1e9b3ab3cfb2Subsidiarie97%

EX21:2db6ac6cf921EX21:2db6ac6cf921Subsidiarie97%

EX21:357d7efe0f65EX21:357d7efe0f65Subsidiarie97%

EX21:3dd279f15794EX21:3dd279f15794Subsidiarie97%

EX21:40659074f19bEX21:40659074f19bSubsidiarie97%

EX21:44473f6c5247EX21:44473f6c5247Subsidiarie97%

EX21:504b7b81e1dbEX21:504b7b81e1dbSubsidiarie97%

EX21:5512d35ee349EX21:5512d35ee349Subsidiarie97%

EX21:678ced8ac81fEX21:678ced8ac81fSubsidiarie97%

EX21:6ab3546aa996EX21:6ab3546aa996Subsidiarie97%

EX21:6bf6e72872e4EX21:6bf6e72872e4Subsidiarie97%

EX21:73070999e686EX21:73070999e686Subsidiarie97%

EX21:755495e7a222EX21:755495e7a222Subsidiarie97%

EX21:792a2cf78b95EX21:792a2cf78b95Subsidiarie97%

EX21:8278ab567213EX21:8278ab567213Subsidiarie97%

EX21:868576b7127eEX21:868576b7127eSubsidiarie97%

EX21:91948c9a2561EX21:91948c9a2561Subsidiarie97%

EX21:92725661416dEX21:92725661416dSubsidiarie97%

EX21:98e2d89ec82dEX21:98e2d89ec82dSubsidiarie97%

EX21:9ff40ee8d33fEX21:9ff40ee8d33fSubsidiarie97%

EX21:a75278fcf85dEX21:a75278fcf85dSubsidiarie97%

EX21:a8821b3f21d7EX21:a8821b3f21d7Subsidiarie97%

EX21:a9ff837fa5f5EX21:a9ff837fa5f5Subsidiarie97%

EX21:aea3988f31d5EX21:aea3988f31d5Subsidiarie97%

EX21:b178871a5a52EX21:b178871a5a52Subsidiarie97%

EX21:b3df20583d32EX21:b3df20583d32Subsidiarie97%

EX21:b3edb18e94e9EX21:b3edb18e94e9Subsidiarie97%

EX21:bb8a4a338d95EX21:bb8a4a338d95Subsidiarie97%

EX21:bbebb4856416EX21:bbebb4856416Subsidiarie97%

EX21:bdb3f039ea4cEX21:bdb3f039ea4cSubsidiarie97%

EX21:c16ba0b07d86EX21:c16ba0b07d86Subsidiarie97%

EX21:c9641178c584EX21:c9641178c584Subsidiarie97%

EX21:d24e07fd9470EX21:d24e07fd9470Subsidiarie97%

EX21:d2c2a1c56d14EX21:d2c2a1c56d14Subsidiarie97%

EX21:d30e4f264aceEX21:d30e4f264aceSubsidiarie97%

EX21:d4e296ba20b3EX21:d4e296ba20b3Subsidiarie97%

EX21:d7f46dbefcd3EX21:d7f46dbefcd3Subsidiarie97%

EX21:da2f6c0767b4EX21:da2f6c0767b4Subsidiarie97%

EX21:dd0984aaf168EX21:dd0984aaf168Subsidiarie97%

EX21:de0af3269015EX21:de0af3269015Subsidiarie97%

EX21:e988f2163886EX21:e988f2163886Subsidiarie97%

EX21:ef79eea6741bEX21:ef79eea6741bSubsidiarie97%

EX21:f1657bc4415aEX21:f1657bc4415aSubsidiarie97%

EX21:f55107e05563EX21:f55107e05563Subsidiarie97%

EX21:f777b07483caEX21:f777b07483caSubsidiarie97%

EX21:fc1021e23badEX21:fc1021e23badSubsidiarie97%

EX21:fc5720973112EX21:fc5720973112Subsidiarie97%

EX21:fc645139452aEX21:fc645139452aSubsidiarie97%

EX21:ff597e78d21fEX21:ff597e78d21fSubsidiarie97%

EX21:ff7e9471297fEX21:ff7e9471297fSubsidiarie97%

Supply chain

— missing data

Peer comparison

Peer comparison8 peers · vs BIO · multiples and returns

ABT—

Abbott Laboratories

$107,13

187,2B USD

P/E

26,3x

+16,2 vs self

Div yield

2,4 %

— vs self

ROE

12,5 %

+2,3 vs self

MDT—

Medtronic PLC

$86,19

110,3B USD

P/E

21,4x

+11,3 vs self

Div yield

3,4 %

— vs self

ROE

9,7 %

-0,5 vs self

MDLN—

MEDLINE INC.

$40,47

53,2B USD

P/E

202,6x

+192,6 vs self

Div yield

—

— vs self

ROE

—

— vs self

SYK—

Stryker Corp

$341,20

131,8B USD

P/E

38,0x

+27,9 vs self

Div yield

—

— vs self

ROE

13,5 %

+3,3 vs self

BDX—

Becton Dickinson And Co

$170,21

48,4B USD

P/E

25,6x

+15,5 vs self

Div yield

2,8 %

— vs self

ROE

7,0 %

-3,2 vs self

HSIC—

Henry Schein Inc

$88,21

10,1B USD

P/E

80,5x

+70,5 vs self

Div yield

—

— vs self

ROE

3,0 %

-7,2 vs self

BAX—

Baxter International Inc

$28,10

14,5B USD

P/E

—

— vs self

Div yield

2,3 %

— vs self

ROE

-15,4 %

-25,6 vs self

SOLV—

SOLVENTUM CORPORATION

$76,83

13,3B USD

P/E

8,6x

-1,5 vs self

Div yield

—

— vs self

ROE

30,8 %

+20,6 vs self

Market position

Stress test

— missing data

Predictor forecast

Next quarternear-term

Earnings · next quarterconf 45 %

EPS

Consensus EPS

0,01

Predicted surprise

+0,00

Beat probability

45 %

Analysts

Other metrics

Revenue

—

no estimate

Segment revenue

—

no estimate

Margin

—

no estimate

Segment margin

—

no estimate

as of 2026-05-10 · Earnings Surprise V1

Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.

Full fiscal year~1 year ahead

Full fiscal year · our forecast vs guidance vs consensus

Metric	Our forecast	Guidance	Consensus
EPS	—no estimate	—no estimate	0,01
Revenue	—no estimate	—no estimate	25,6M AUD
Operating income	—no estimate	—no estimate	3,6M AUD

Full-year consensus mean (period as reported by source) · consensus in AUD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.

Probabilistic model output — not investment advice. · generated 2026-08-04

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Consensus distribution

sell-side coverage

Recommendation distribution1 analysts

Strong buy0

Buy1

Hold0

Sell0

Strong sell0

12-month price targetA$1,00 · Median A$1,00

Low A$1,00High A$1,00

Operating income · consensus3,6M AUD

EPS surprise

−93,3 %

reported vs consensus · miss

Revenue surprise

−28,1 %

reported vs consensus · miss

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

LowA$1,00

MeanA$1,00

MedianA$1,00

HighA$1,00

SpotA$0,28

+263.6 %implied to mean12-month sell-side price targets · ▲ spot

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskMedium

Filing-based flags

Net cash is negative after subtracting total debt.

Benchmarks vs cohort

Op Margin1,2 %Above median

Net Margin1,2 %Above median

ROE4,6 %Above median

Capex / Rev-1,1 %Above median

D/E0,66Bottom quartile

Cash Conv-13,14Bottom quartile

Corporate actions / M&A

M&A probabilityconf —

Probability

3 %

Base rate

3 %

Band

Low

180-day horizon · target 2027-01-31 · 1,0× base rate

No acquirer candidates identified by the signal model.

Corporate actionsNo corporate-action source connected yet — splits, dividends and buyback events are not tracked for this company. Honest-dim (no data fabricated).

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

Derivative transactions

Net acquired 32 523 sh29 exercises · 15 grants14 insiders

ENGELHARDT EVA ANETTEEVP, President, CDG · Restricted Stock Units → Bio-Rad A Common StockDisposed 246exercise · 2026-07-25
ENLOE COURTNEY CEVP, General Counsel & Sec · Restricted Stock Units → Bio-Rad A Common StockDisposed 186exercise · 2026-04-24
Lakkaraju Roop KalyanEVP, Chief Financial Officer · Restricted Stock Units → Bio-Rad A Common StockDisposed 1 078exercise · 2026-04-24
PINKSTON ARNOLD ADirector · Restricted Stock Units → Bio-Rad A Common StockAcquired 369grant · 2026-04-21
EDWARDS JEFFREY LDirector · Restricted Stock Units → Bio-Rad A Common StockDisposed 407exercise · 2026-04-21
EDWARDS JEFFREY LDirector · Restricted Stock Units → Bio-Rad A Common StockAcquired 369grant · 2026-04-21
PEI MELINDA LITHERLANDDirector · Restricted Stock Units → Bio-Rad A Common StockDisposed 407exercise · 2026-04-21
PEI MELINDA LITHERLANDDirector · Restricted Stock Units → Bio-Rad A Common StockAcquired 369grant · 2026-04-21
Hinckley Greg KDirector · Restricted Stock Units → Bio-Rad A Common StockDisposed 407exercise · 2026-04-21
Hinckley Greg KDirector · Restricted Stock Units → Bio-Rad A Common StockAcquired 369grant · 2026-04-21
PINKSTON ARNOLD ADirector · Restricted Stock Units → Bio-Rad A Common StockDisposed 407exercise · 2026-04-21
DiVincenzo Jonathan P.President & COO · Restricted Stock Units → Bio-Rad A Common StockDisposed 1 869exercise · 2025-10-24
EVRAN SEDATEVP, Global Supply Chain · Restricted Stock Units → Bio-Rad A Common StockDisposed 1 044exercise · 2025-10-20
SCHWARTZ NORMAN DDirector, Chairman & CEO, 10% owner · Restricted Stock Units → Bio-Rad A Common StockDisposed 3 455exercise · 2025-09-06
Lakkaraju Roop KalyanEVP, Chief Financial Officer · Restricted Stock Units → Bio-Rad A Common StockDisposed 1 535exercise · 2025-09-06
ENGELHARDT EVA ANETTEEVP, President, CDG · Restricted Stock Units → Bio-Rad A Common StockDisposed 1 152exercise · 2025-09-06
Allison SchwartzDirector · Restricted Stock Units → Bio-Rad A Common StockDisposed 92exercise · 2025-09-06
BARRY JAMESEVP, President, LSG · Restricted Stock Units → Bio-Rad A Common StockDisposed 1 056exercise · 2025-09-06
ENLOE COURTNEY CEVP, General Counsel & Sec · Restricted Stock Units → Bio-Rad A Common StockDisposed 768exercise · 2025-09-06
EVRAN SEDATEVP, Global Supply Chain · Restricted Stock Units → Bio-Rad A Common StockDisposed 864exercise · 2025-09-06
COREY COLLEENEVP, Global Human Resources · Restricted Stock Units → Bio-Rad A Common StockDisposed 576exercise · 2025-09-06
BARRY JAMESEVP, President, LSG · Restricted Stock Units → Bio-Rad A Common StockAcquired 4 110grant · 2025-09-05
COREY COLLEENEVP, Global Human Resources · Restricted Stock Units → Bio-Rad A Common StockAcquired 2 740grant · 2025-09-05
Lakkaraju Roop KalyanEVP, Chief Financial Officer · Restricted Stock Units → Bio-Rad A Common StockAcquired 5 480grant · 2025-09-05
EVRAN SEDATEVP, Global Supply Chain · Restricted Stock Units → Bio-Rad A Common StockAcquired 4 110grant · 2025-09-05

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Return On Equity
net_income / total_equity
Price To Earnings
market_price / (net_income / shares_outstanding_diluted)
Price To Book
market_price / (adjusted_book_value / shares_outstanding_diluted)
Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Market Price
input from market-data provider (delayed close or quote-shim mid)
Market Cap
market_price * shares_outstanding_diluted

Source documents

BIO.AX Market data — financials · 2026-05-27
Biome Australia Ltd Market data — analyst estimates · 2026-05-27

Ownership & reference

Top holders

Dimensional Fund Advisors, L.P.Investment Managers · as of 2026-03-310,06 %$304M
MASSACHUSETTS FINANCIAL SERVICES CO /MA/Institutional Investor · as of 2026-03-310,04 %$110M
Capital Research Global InvestorsInvestment Managers · as of 2026-03-310,02 %$125M
AQR Capital Management, LLCInvestment Managers · as of 2026-03-310,01 %$26M
Franklin Advisers, Inc.Investment Managers · as of 2026-03-310,01 %$47M
Fisher InvestmentsInvestment Managers · as of 2026-03-310,01 %$33M
BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,01 %$423M
JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,01 %$19M
Charles Schwab Investment Management, Inc.Investment Managers · as of 2026-03-310,01 %$55M
Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,01 %$61M
Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,01 %$538M
Bank of New York Mellon CorpInstitutional Investor · as of 2026-03-310,01 %$35M
Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,01 %$102M
Principal Global Investors (Equity)Investment Managers · as of 2026-03-310,01 %$11M
State Street Investment Management (US)Investment Managers · as of 2026-03-310,01 %$156M
Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$76M
EATON VANCE MANAGEMENTInstitutional Investor · as of 2022-09-300,00 %$0M
Nuveen LLCInvestment Managers · as of 2024-12-310,00 %$13M
Victory Capital Management Inc.Investment Managers · as of 2026-03-310,00 %$5M
Raymond James & Associates, Inc.Brokerage Firms · as of 2026-03-310,00 %$10M
AllianceBernstein L.P.Investment Managers · as of 2026-03-310,00 %$7M
T. Rowe Price Associates, Inc.Investment Managers · as of 2026-03-310,00 %$0M
Arrowstreet Capital, Limited PartnershipInvestment Managers · as of 2026-03-310,00 %$4M
Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$15M
Invesco QQQ TrustFunds · as of 2026-03-310,00 %$10M
LPL Financial LLCInvestment Managers · as of 2026-03-310,00 %$5M
AMERIPRISE FINANCIAL INCInstitutional Investor · as of 2026-03-310,00 %$5M
JANUS HENDERSON GROUP PLCInstitutional Investor · as of 2026-03-310,00 %$2M
American Century Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$2M
PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$1M
First Trust Advisors L.P.Investment Managers · as of 2026-03-310,00 %$0M
FMR LLCInstitutional Investor · as of 2026-03-310,00 %$1M
PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$0M
Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$0M
JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$0M
UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$0M

Insider activity

Net selling0 buys · 2 sellsnet -$350K13 insiders · last 365d

ENGELHARDT EVA ANETTEEVP, President, CDG · Bio-Rad A Common StockOther 89 @ $314,46$28K · 2026-07-25
ENGELHARDT EVA ANETTEEVP, President, CDG · Bio-Rad A Common StockOther 246 · 2026-07-25
ENGELHARDT EVA ANETTEEVP, President, CDG · Bio-Rad A Common StockSold 550 @ $246,54$136K · 2026-05-11
Lakkaraju Roop KalyanEVP, Chief Financial Officer · Bio-Rad A Common StockOther 1 078 · 2026-04-24
Lakkaraju Roop KalyanEVP, Chief Financial Officer · Bio-Rad A Common StockOther 420 @ $287,84$121K · 2026-04-24
ENLOE COURTNEY CEVP, General Counsel & Sec · Bio-Rad A Common StockOther 186 · 2026-04-24
ENLOE COURTNEY CEVP, General Counsel & Sec · Bio-Rad A Common StockOther 77 @ $287,84$22K · 2026-04-24
Hinckley Greg KDirector · Bio-Rad A Common StockOther 407 · 2026-04-21
PEI MELINDA LITHERLANDDirector · Bio-Rad A Common StockOther 407 · 2026-04-21
EDWARDS JEFFREY LDirector · Bio-Rad A Common StockOther 407 · 2026-04-21
PINKSTON ARNOLD ADirector · Bio-Rad A Common StockOther 407 · 2026-04-21
BARRY JAMESEVP, President, LSG · Bio-Rad A Common StockSold 700 @ $306,18$214K · 2025-11-06
DiVincenzo Jonathan P.President & COO · Bio-Rad A Common StockOther 1 869 · 2025-10-24
DiVincenzo Jonathan P.President & COO · Bio-Rad A Common StockOther 950 @ $339,75$323K · 2025-10-24
EVRAN SEDATEVP, Global Supply Chain · Bio-Rad A Common StockOther 1 044 · 2025-10-20
EVRAN SEDATEVP, Global Supply Chain · Bio-Rad A Common StockOther 335 @ $321,90$108K · 2025-10-20
SCHWARTZ NORMAN DDirector, Chairman & CEO, 10% owner · Bio-Rad A Common StockOther 1 528 @ $295,43$451K · 2025-09-06
EVRAN SEDATEVP, Global Supply Chain · Bio-Rad A Common StockOther 864 · 2025-09-06
EVRAN SEDATEVP, Global Supply Chain · Bio-Rad A Common StockOther 277 @ $295,43$82K · 2025-09-06
Lakkaraju Roop KalyanEVP, Chief Financial Officer · Bio-Rad A Common StockOther 1 535 · 2025-09-06
Lakkaraju Roop KalyanEVP, Chief Financial Officer · Bio-Rad A Common StockOther 550 @ $295,43$162K · 2025-09-06
COREY COLLEENEVP, Global Human Resources · Bio-Rad A Common StockOther 576 · 2025-09-06
COREY COLLEENEVP, Global Human Resources · Bio-Rad A Common StockOther 209 @ $295,43$62K · 2025-09-06
BARRY JAMESEVP, President, LSG · Bio-Rad A Common StockOther 1 056 · 2025-09-06
BARRY JAMESEVP, President, LSG · Bio-Rad A Common StockOther 378 @ $295,43$112K · 2025-09-06

Short positioning

1.6Mshares short+2.8% vs prior

5.96days to cover

85.1%short of daily vol

36fails-to-deliver

as of 2026-07-15 · short-interest report (free)

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

BIO.AXCanonical

ASX · AUD

Intel & risk

PredictorBeat prob45 %Surprise+0,00Full forecast →

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskMedium

Net cash is negative after subtracting total debt.

Relationship graph

This companySectorSubsidiaries

Evidence & claims

From filings & derived data

Net income (YoY) (2025-12-31 vs 2024-12-31): 141.2%Derived (calculated)
Revenue (YoY) (2025-12-31 vs 2024-12-31): 0.7%Derived (calculated)
Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 16.9%Derived (calculated)
Operating income (YoY) (2025-12-31 vs 2024-12-31): -82.5%Derived (calculated)
R&D expense (YoY) (2025-12-31 vs 2024-12-31): -6.9%Derived (calculated)
Total assets (YoY) (2025-12-31 vs 2024-12-31): 12.9%Derived (calculated)
Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 11.7%Derived (calculated)
Net margin (FY 2025-12-31): 29.4%Derived (calculated)
Gross margin (FY 2025-12-31): 51.9%Derived (calculated)
Return on equity (FY 2025-12-31): 10.2%Derived (calculated)
Return on assets (FY 2025-12-31): 7.2%Derived (calculated)
Current ratio (FY 2025-12-31): 5.62xDerived (calculated)
Debt-to-equity (FY 2025-12-31): 0.42xDerived (calculated)
Capex (YoY) (2025-12-31 vs 2024-12-31): -4.8%Derived (calculated)
Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 8.5%Derived (calculated)
Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): 4.7%Derived (calculated)
EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 142.6%Derived (calculated)
EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 142.6%Derived (calculated)
Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 13.5%Derived (calculated)
Gross profit (YoY) (2025-12-31 vs 2024-12-31): -2.8%Derived (calculated)
Long-term debt (YoY) (2025-12-31 vs 2024-12-31): 0.2%Derived (calculated)
Operating income (annual): USD 47.2MSEC XBRL filing
EPS (basic) (annual): USD-PER-SHARES 28SEC XBRL filing
Capex (annual): USD 157.6MSEC XBRL filing

Showing 24 of 60 surfaced claims.

Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

The Thread

Everything we know, in order

2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date

2026-08-04 00:00 UTCTRANSCRIPTEarnings call — Q3 2026

2026-07-25INSIDERENGELHARDT EVA ANETTE transacted 246 sh Bio-Rad A Common Stock — EVP, President, CDG

2026-07-25INSIDERENGELHARDT EVA ANETTE transacted 89 sh Bio-Rad A Common Stock — EVP, President, CDG ~$28k

2026-07-25INSIDERENGELHARDT EVA ANETTE disposed of 246 sh Restricted Stock Units — EVP, President, CDG

2026-07-04 03:13 UTCHOLDERInstitutional holding changed

2026-07-04 03:13 UTCHOLDER1 institutional position change flagged (1 major)

2026-07-03 03:12 UTCHOLDERInstitutional holding changed

2026-07-03 03:12 UTCHOLDER2 institutional position changes flagged (2 major)

2026-07-01 03:10 UTCHOLDERInstitutional holding changed

2026-07-01 03:10 UTCHOLDER1 institutional position change flagged (1 major)

2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)

2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (365d)

2026-06-30 03:38 UTCEARNINGSUpcomingForecast: ma_probability (180d)

2026-06-30 03:14 UTCHOLDERInstitutional holding changed

2026-06-30 03:14 UTCHOLDER4 institutional position changes flagged (2 major)

2026-06-28 03:14 UTCHOLDER1 institutional position change flagged (1 major)

2026-06-26 03:13 UTCHOLDER1 institutional position change flagged (1 major)

2026-06-25 03:10 UTCHOLDER1 institutional position change flagged (1 major)

2026-06-23 03:11 UTCHOLDER2 institutional position changes flagged (2 major)

2026-06-21 02:57 UTCHOLDER1 institutional position change flagged (1 major)

2026-05-11 00:00 UTCINSIDER1 insider transaction — 2026-05 · net sell $136k

2026-05-11INSIDERENGELHARDT EVA ANETTE sold 550 sh Bio-Rad A Common Stock — EVP, President, CDG ~$136k

2026-05-01 12:19 UTCFILINGRegulatory filing →

2026-04-30FILING10-Q filing →

2026-04-30FILING8-K filing →

2026-04-24 00:00 UTCINSIDER18 insider transactions — 2026-04 · net sell $143k 10 derivative

2026-04-24FILING8-K filing →

2026-04-24INSIDERLakkaraju Roop Kalyan transacted 1.1k sh Bio-Rad A Common Stock — EVP, Chief Financial Officer

2026-04-24INSIDERLakkaraju Roop Kalyan transacted 420 sh Bio-Rad A Common Stock — EVP, Chief Financial Officer ~$121k

2026-04-24INSIDERENLOE COURTNEY C transacted 186 sh Bio-Rad A Common Stock — EVP, General Counsel & Sec

2026-04-24INSIDERENLOE COURTNEY C transacted 77 sh Bio-Rad A Common Stock — EVP, General Counsel & Sec ~$22k

2026-04-24INSIDERENLOE COURTNEY C disposed of 186 sh Restricted Stock Units — EVP, General Counsel & Sec

Showing the 40 most recent of 84 entries.

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

Analyst recommendations

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Consensus distribution

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Derivative transactions

Actions

Ask Handelsavisen

Ownership & reference

Top holders

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread